High-Tech Gründerfonds, Creathor Ventures, KfW and Bayern Kapital have announced that they are committed to sell their shares of SIRION Biotech GmbH, a global provider of viral vector-based technologies that drive improved delivery performance for cell and gene therapies.
High-Tech Gründerfonds, Creathor Ventures, KfW and Bayern Kapital have announced that they are committed to sell their shares of SIRION Biotech GmbH, a global provider of viral vector-based technologies that drive improved delivery performance for cell and gene therapies.
This news comes after PerkinElmer, Inc announced that it has entered into an agreement to acquire SIRION. The acquisition is expected to close during the third quarter of 2021.
In 2007 Creathor Ventures, High-Tech Gründerfonds, Bayern Kapital and KfW syndicated in a first seed financing round of SIRION. Headquartered in Munich, Germany, privately held SIRION has approximately 50 employees based in Germany, the US and France. The company has established a strong licensing portfolio leveraged by over a dozen major pharmaceutical and biotech players researching more than twenty-five diseases and conditions.
Dr Christian Thirion, CEO of SIRION, comments: “Our team is excited to work with PerkinElmer to continue to grow our leading position in viral vector technologies for cell and gene therapy. We will benefit greatly from becoming part of the PerkinElmer portfolio, with increased access to genomics analysis, gene editing and base editing technologies, as well as a strong global infrastructure and reach.”
Marco Winzer, Partner at HTGF, states: “We are very proud to have played a part in SIRION’s successful development. As a seed investor, we are always on the lookout for high-potential technologies prior to market launch as well as highly motivated entrepreneurs and teams. SIRION delivered on all these aspects.”
Karlheinz Schmelig, Partner at Creathor Ventures, adds: “SIRION is a great example of founders and management teaming up with experienced investors to bring an early-stage scientific innovation from the academic lab bench to world-wide technology leadership. We are very pleased to have played an active role in this success story.”
Roman Huber, Managing Director at Bayern Kapital adds: “From the very beginning, we have been very impressed with SIRION’s technical knowledge and market expertise, and have been actively supporting the company’s growth over the years as of the earliest stage. We are therefore very pleased with this great success and wish SIRION the very best.”
